V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330011066 | 330006107 | 1.7 | 75.7 | Palliative (P) | null | 2019-08-30 | STS Rhabdomyosarcoma RMS 2005 VA | N | 1 | 330019201 | AML17 TRIAL |
| 330011067 | 330006108 | 1.6 | 126 | Palliative (P) | 2016-08-23 | 2016-09-08 | Ifosfamide | 02 | N | 330019649 | ERLOTINIB |
| 330011068 | 330006111 | 0 | null | Neo-adjuvant (N) | 2018-07-30 | 2018-12-27 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 330020297 | EC |
| 330011069 | 330006113 | 1.61 | null | Palliative (P) | 2017-08-27 | 2017-09-11 | Topotecan (intravenous) | N | N | 330020339 | FCIST |
| 330011070 | 330006116 | null | 7.5 | Curative (C) | null | 2019-05-19 | CNS LGG 2004 03 vinc weekly+ carbo | N | null | 330020434 | DHAP |
| 330011071 | 330006116 | 1.68 | null | Curative (C) | 2013-05-23 | 2013-06-13 | Cyclophosphamide + Vincristine | 2 | N | 330020434 | CYCLOPHOSPHAMIDE + VINORELBINE |
| 330011072 | 330006117 | 1.54 | null | Palliative (P) | 2017-02-23 | 2017-08-31 | PEMBROLIZUMAB | 02 | N | 330020661 | CISPLATIN + VINORELBINE |
| 330011073 | 330006119 | 1.8 | 73.85 | Adjuvant (A) | null | 2017-10-20 | CVP R | N | N | 330020744 | CISPLATIN + DOXORUBICIN + METHOTREXATE |
| 330011074 | 330006120 | 0 | 100.3 | Palliative (P) | 2017-12-16 | 2017-12-18 | CYCLOPHOSPHAMIDE | 02 | N | 330020797 | RMS 2005 TRIAL |
| 330011075 | 330006121 | 1.84 | 72 | Palliative (P) | 2017-09-04 | 2017-09-05 | Dacarbazine | 2 | N | 330020858 | CETUXIMAB + CISPLATIN + FU |
| 330011076 | 330006123 | null | null | Curative (C) | 2018-10-08 | 2018-10-08 | DE-ESCALATE TRIAL | N | N | 330020918 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330011077 | 330009340 | 1.69 | 90.2 | Palliative (P) | 2019-08-27 | 2019-08-28 | LIPOSOMAL DAUNORUBICIN | N | N | 330020943 | IVA |
| 330011078 | 330006125 | 1.6 | 59 | Disease modification (D) | 2016-04-26 | 2016-05-27 | Pazopanib | 2 | N | 330020986 | CAPECITABINE + OXALIPLATIN |
| 330011079 | 330009341 | 1.64 | null | Palliative (P) | 2017-07-26 | 2018-04-05 | Cytarabine intrathecal | 02 | N | 330021072 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330011080 | 330006127 | 1.65 | null | Curative (C) | 2015-02-02 | 2015-11-07 | Capecitabine 42days + RT | Y | N | 330021091 | PEMBROLIZUMAB |
| 330011081 | 330006130 | null | null | Palliative (P) | 2018-03-29 | 2018-04-02 | Cetuximab +Cisplatin + FU (Cycle 1) | N | N | 330021094 | TIP |
| 330011082 | 330011093 | 1.8 | 72 | Palliative (P) | null | 2018-07-27 | STS Rhabdomyosarcoma RMS 2005 VA | N | N | 330021332 | DOXORUBICIN + HD MTX |
| 330011083 | 330006133 | 1.49 | 54 | Disease modification (D) | 2015-12-21 | 2016-04-13 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | N | null | 330021494 | CYTARABINE |
| 330011084 | 330006135 | null | 8.8 | null | 2017-02-27 | 2017-03-04 | Doxorubicin + Methotrexate | Y | null | 330021705 | VIDE |
| 330011085 | 330012046 | null | 140.8 | Palliative (P) | 2018-10-22 | 2018-11-23 | IVA | null | null | 330021777 | THALIDOMIDE |
| 330011086 | 330006138 | 1.56 | 62.25 | Palliative (P) | 2017-12-30 | 2018-01-09 | PEMBROLIZUMAB | 2 | N | 330021961 | EMA |
| 330011087 | 330009346 | 0 | 43.4 | Palliative (P) | 2013-10-30 | 2014-01-12 | CAP | N | N | 330022129 | CLADRIBINE |
| 330011088 | 330006140 | 1.52 | 82 | Curative (C) | null | 2017-04-05 | VIDE | N | N | 330022918 | RUXOLITINIB |
| 330011089 | 330006142 | 1.69 | 61.5 | Neo-adjuvant (N) | 2016-05-03 | 2016-06-21 | Capecitabine (21days) + Carboplatin | 2 | N | 330023337 | ERLOTINIB |
| 330011090 | 330006142 | 1.77 | null | Disease modification (D) | 2017-03-23 | 2017-06-14 | NB BEACON Temoz Irin Bev | N | null | 330023337 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |
| 330011091 | 330013102 | null | 77.3 | Curative (C) | 2017-04-20 | 2017-04-20 | CISPLATIN + DACTINOMYCIN + ETOPOSIDE + METHOTREXATE | N | N | 330023936 | UKALL2014 |
| 330011092 | 330013303 | 1.88 | 64 | null | 2015-11-07 | 2015-12-09 | CETUXIMAB + CISPLATIN + FU | Y | N | 330024602 | CISPLATIN + VINORELBINE |
| 330011093 | 330006144 | 1.67 | 6.6 | Curative (C) | 2016-01-07 | 2016-01-13 | CAPECITABINE + OXALIPLATIN | Y | N | 330024623 | DOXORUBICIN + IFOSFAMIDE |
| 330011094 | 330006147 | 1.83 | 98.4 | Palliative (P) | 2016-09-16 | 2016-12-14 | Capecitabine (14 days)+Carboplatin | N | N | 330025015 | FLUDARABINE |
| 330011095 | 330006150 | 0 | null | null | 2016-09-01 | 2017-08-06 | Clofarabine + Cytarabine | N | N | 330003175 | CYTARABINE |
| 330011096 | 330009351 | 1.69 | 38.9 | Adjuvant (A) | 2017-05-18 | 2017-05-18 | CAELYX + CYCLOPHOSPHAMIDE + VINCRISTINE | N | N | 330007206 | ETOPOSIDE + MELPHALAN |
| 330011097 | 330006157 | null | null | null | 2018-11-26 | 2018-12-31 | CAPECITABINE + VINORELBINE | N | null | 330009579 | DASATINIB |
| 330011098 | 330006162 | null | 91.6 | Curative (C) | null | 2018-07-08 | Bendamustine +/- Prednisolone | null | null | 330020726 | RMS 2005 TRIAL |
| 330011099 | 330006164 | null | null | Palliative (P) | 2017-04-16 | 2017-07-16 | CAPECITABINE + OXALIPLATIN | 01 | N | 330021584 | CYCLOPHOSPHAMIDE + VINORELBINE |
| 330011100 | 330006166 | 1.65 | 56.5 | Palliative (P) | 2017-08-03 | 2017-08-03 | VIDE | 02 | N | 330000232 | MITOTANE |
| 330011101 | 330002931 | 0 | 73 | Palliative (P) | 2015-11-15 | 2016-06-08 | NB HRNBL-1 COJEC Ind COURSE B | Y | Y | 330000004 | NOT MATCHED |
| 330011102 | 330002937 | 0 | 11.6 | Curative (C) | 2014-04-04 | 2014-05-06 | NB HRNBL-1 COJEC Ind COURSE B | null | Y | 330000050 | NOT MATCHED |
| 330011104 | 330002950 | 0 | 14.4 | Curative (C) | 2018-04-03 | 2018-06-03 | NB HRNBL-1 BUMEL MAT | null | null | 330000081 | NOT MATCHED |
| 330011105 | 330002954 | 1.72 | 68.9 | Curative (C) | 2018-02-23 | 2018-02-26 | Cisplatin 100 + RT(H&N) 1 day | N | Y | 330000102 | CISPLATIN + RT |
| 330011106 | 330007584 | 0.8 | 19.3 | Curative (C) | 2013-10-21 | 2014-05-20 | NB HRNBL-1 MOD N7 PE | Y | null | 330000122 | NOT MATCHED |
| 330011107 | 330007587 | 0.75 | 20.1 | Neo-adjuvant (N) | 2017-12-12 | 2017-12-12 | AML Interim Guidelines | 01 | N | 330000144 | NOT MATCHED |
| 330011108 | 330002967 | 1.54 | 59.7 | Curative (C) | 2015-07-25 | 2018-04-22 | Cisplatin 100 + RT(H&N) 1 day | 02 | Y | 330000163 | CISPLATIN + RT |
| 330011109 | 330002971 | 0 | 23.5 | Curative (C) | 2016-09-22 | 2017-02-16 | NB HRNBL-1 COJEC Ind COURSE C | 01 | N | 330000172 | NOT MATCHED |
| 330011110 | 330002983 | 0 | 11.5 | Curative (C) | 2014-09-12 | 2014-11-09 | NB Rel CCLG guidelines Cyclo-Topotecan | N | N | 330000242 | NOT MATCHED |
| 330011111 | 330002988 | 1.81 | 23.8 | Neo-adjuvant (N) | 2016-11-04 | 2016-11-04 | NB HRNBL-1 COJEC Ind COURSE C | Y | N | 330000247 | NOT MATCHED |
| 330011112 | 330002992 | 0 | 57.1 | Curative (C) | 2017-04-14 | 2017-08-03 | CNS LGG 2004 03 con vinc +cisplatin | N | null | 330000263 | NOT MATCHED |
| 330011113 | 330010140 | 1.62 | 10.3 | Curative (C) | 2016-03-15 | 2016-03-15 | NB HRNBL-1 BUMEL MAT | N | N | 330000276 | NOT MATCHED |
| 330011114 | 330002996 | 0 | 7.4 | Curative (C) | null | 2015-06-26 | NB HRNBL-1 COJEC Ind COURSE C | null | N | 330000277 | NOT MATCHED |
| 330011115 | 330003000 | 1.52 | 12.9 | Curative (C) | 2017-12-21 | 2018-01-04 | NB HRNBL-1 Isotretinoin | 02 | N | 330000299 | NOT MATCHED |
| 330011116 | 330003003 | 0.87 | 12.6 | Adjuvant (A) | 2014-09-28 | 2014-09-28 | NB HRNBL-1 COJEC Ind COURSE C | 02 | null | 330000305 | NOT MATCHED |